The global pharmaceutical industry experienced a 28% decline in the number of Covid-19-related patent applications in Q2 2024 compared with the previous quarter. The total number of Covid-19-related grants dropped by 18% in Q2 2024, according to GlobalData’s Patent Analytics. GlobalData’s databook Pharma: Patents Trends Q2 2024 offers comprehensive insights into patenting trends, major players’ strategies, and geographical focus in the sector over the last three years. Buy the databook here.
Notably, the number of Covid-19-related patent applications in the pharmaceutical industry was 693 in Q2 2024, versus 965 in the prior quarter.
The top five companies accounted for 5% of patenting activity
Analysis of patenting activity by companies shows that Scripps Research Institute filed the most Covid-19 patents within the pharmaceutical industry in Q2 2024. The company filed 10 Covid-19-related patents in the quarter, compared with 3 in the previous quarter. It was followed by Columbia University with 7 Covid-19 patent filings, Stanford University (7 filings), and GSK (6 filings) in Q2 2024.
Patenting activity was driven by the US with a 47% share of total patent filings
The largest share of Covid-19 related patent filings in the pharmaceutical industry in Q2 2024 was in the US with 47%, followed by China (11%) and Australia (6%). The share represented by the US was 10% higher than the 37% share it accounted for in Q1 2024.
For further understanding of GlobalData's Pharma: Patents Trends Q2 2024, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.